Lipid Nanoparticle Raw Materials Market Size was valued at USD 230.23 Mn in 2023 and is predicted to reach USD 356.05 Mn by the year 2031 at a 5.80% CAGR during the forecast period for 2024-2031.
Lipids, stabilizers, and occasionally targeting ligands make up the different raw elements that make up lipid nanoparticles. Phospholipids, such as phosphatidylcholine and cholesterol, are often utilized lipids. Several important reasons are driving the growth of the market for raw materials for lipid nanoparticles. One major driver is the growing need for sophisticated drug delivery systems, of which lipid nanoparticles are essential building blocks. Lipid nanoparticles' growing popularity can be attributed to their capacity to encapsulate a variety of therapeutic payloads, improving targeted and regulated drug delivery. Furthermore, the realm of nanotechnology is seeing swift progress, which is contributing to the expansion of the industry. Lipid nanoparticles' distinct qualities make them excellent options for a range of uses, such as imaging and diagnostics, which increases their market appeal.
Furthermore, lipid nanoparticle raw materials market has grown significantly due to the pharmaceutical and biotech industries' increased spending on research and development. This tendency is anticipated to result in the development of innovative applications and formulations, supporting long-term market expansion.
Competitive Landscape
Some of the Major Key Players in the Lipid Nanoparticle Raw Materials Market are
- Echelon Biosciences
- BroadPharm
- Biopharma PEG Scientific Inc.
- NOF AMERICA CORPORATION
- CordenPharma International
- Merck KGaA
- Avanti Polar Lipids
- Tebubio
- Creative Biolabs
- Polysciences, Inc.
- Precision NanoSystems (Cytiva)
- Evonik Industries AG
- Nippon Fine Chemical
- Lipoid GmbH
- CLARIANT
Market Segmentation:
The lipid nanoparticle raw materials market is segmented on the basis of application, product, disease indication, and end-use. Based on application, the market is segmented as therapeutics and research. By product, the market is segmented into ionizable lipids (PEGylated lipids, sterol lipids, neutral phospholipids), kits, reagents, and other raw materials. Based on disease indication, the market is segmented into cancer, infectious diseases, blood diseases, and others. On the basis of end-use, the market is segmented into pharmaceutical & biotechnology companies, academic & research institutes, and others.
Based on Application, the Therapeutics Segment is Accounted as a Major Contributor in the Lipid Nanoparticle Raw Materials Market
The therapeutics category is expected to hold a major share of the global lipid nanoparticle raw materials market in 2022. This dominance can be linked to the pharmaceutical industry's extensive usage of lipid nanoparticles (LNPs) for medication delivery. The potential of LNPs to encapsulate and deliver therapeutic substances to specific sites inside the body is impressive. Lipid nanoparticle raw materials are in high demand due to the ongoing rise in the requirement for novel medication delivery systems.
Infectious Diseases Segment Witness Growth at a Rapid Rate
The infectious diseases segment is projected to grow at a rapid rate in the global lipid nanoparticle raw materials market. This significance might be ascribed to Lipid Nanoparticles' (LNPs') crucial involvement in the creation of mRNA vaccines, especially in the international effort to combat COVID-19. LNPs are essential for preventing mRNA from being broken down in the body and for making it easier for mRNA to reach the cells. The global adoption of immunization programs has directly led to a significant rise in the demand for raw materials for lipid nanoparticles.
In the Region, the North America Lipid Nanoparticle Raw Materials Market Holds Significant Revenue Share.
The North America lipid nanoparticle raw materials market is expected to register highest market share in terms of revenue in the near future. This significance is mostly due to the region's thriving biotechnology and pharmaceutical industries. The pharmaceutical and biotech industries in the United States and Canada, in particular, make significant investments in research and development, which in turn drives the demand for drug delivery systems based on lipid nanoparticles. In addition, Asia Pacific is projected to grow at a rapid rate in the global lipid nanoparticle raw materials market. The swift economic expansion of the area has resulted in a rise in healthcare costs and a higher allocation of resources towards medical research and development. Lipid nanoparticles and other innovative drug delivery methods are becoming more and more in demand as a result of the expansion of healthcare services and the enhancement of healthcare infrastructure.
Recent Developments:
- February 2024: University of Pennsylvania researchers in the United States have developed a unique high-throughput screening tool designed for evaluating mRNA enclosed in lipid nanoparticles. With the help of this cutting-edge platform, large libraries of LNPs intended for brain targeting may be quickly screened. Its application accelerates the development of gene editing treatments by assessing and fine-tuning LNPs meant for brain delivery.
- July 2023: A formulation technique from Cytiva has been made available to enable the seamless production of lipid nanoparticle medications at both the clinical and commercial stages. By streamlining the procedure, this method makes it possible to produce lipid nanoparticle-based drugs effectively and completely, from development to commercialization.
Lipid Nanoparticle Raw Materials Market Report Scope
|
Report Attribute |
Specifications |
|
Market Size Value In 2023 |
USD 230.23 Mn |
|
Revenue Forecast In 2031 |
USD 356.05 Mn |
|
Growth Rate CAGR |
CAGR of 5.80% from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Mn and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Application, By Product, By Disease Indication, By End-user and By Region |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
|
Competitive Landscape |
Echelon Biosciences, BroadPharm, Biopharma PEG Scientific Inc., NOF AMERICA CORPORATION, CordenPharma International, Merck KGaA, Avanti Polar Lipids, Tebubio, Creative Biolabs, Polysciences, Inc., Precision NanoSystems (Cytiva), Evonik Industries AG, Nippon Fine Chemical, Lipoid GmbH and CLARIANT. |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
